NCT07612566Not yet recruiting
Immune Repertoire Decoding for Chronic Pancreatitis-to-Pancreatic Cancer Risk Stratification
Immune Repertoire Decoding Enables Dynamic Risk Stratification During Chronic Pancreatitis-to-Pancreatic Cancer Transition
Source: ClinicalTrials.gov · Last updated 28 May 2026
Brief summary (registry, in English)
This study will follow people with chronic pancreatitis, people with pancreatic cancer, and healthy volunteers. The goal is to better understand why some people with chronic pancreatitis may later develop pancreatic cancer. Participants will provide blood samples and health information. Some participants may also provide tissue samples if these are available during routine medical care. The study team will look for changes in the immune system, genes, medical images, and clinical information that may be linked to the development of pancreatic cancer. People with chronic pancreatitis will be followed over time. The information collected in this study may help researchers develop a model to identify patients with chronic pancreatitis who have a higher risk of pancreatic cancer.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 800 (estimated)
- First submitted
- 21 May 2026
- Start date
- 1 Jun 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Changhai Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT07612566
What you commit to
- Study type: Observational
- Planned participants: 800
- From 1 Jun 2026 to the primary completion date, 31 Dec 2028
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior diagnosis of another active malignant tumor, except adequately treated non-melanoma skin cancer or carcinoma in situ, if considered not to affect study participation by the investigator.
- Use of systemic immunosuppressive therapy or immunotherapy within a period considered clinically relevant by the investigator.
Other illness
- Current severe acute infection or other serious medical condition that, in the investigator's judgment, may interfere with study participation or interpretation of immune-related analyses.
- Any condition that, in the investigator's judgment, makes the participant unsuitable for this study.
Other
- Unable or unwilling to provide written informed consent.
- Unable to provide required clinical information or biological samples.
Who the study is looking for
- Adults aged 18 years or older.
- Able to understand the study procedures and provide written informed consent.
- Healthy controls: participants without a known history of chronic pancreatitis or pancreatic cancer.
- Chronic pancreatitis cohort: participants diagnosed with chronic pancreatitis according to clinical guidelines, based on clinical, imaging, and/or genetic information.
- Pancreatic ductal adenocarcinoma cohort: participants with newly diagnosed pancreatic ductal adenocarcinoma based on clinical, imaging, and/or pathological evaluation.
- Willing to provide blood samples and relevant clinical information.
- For participants with chronic pancreatitis, willing to undergo longitudinal follow-up approximately every 6 to 12 months.
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.